Company registration number 11881781 (England and Wales)
BLUEBELL AESTHETICS CLINIC LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
Affinia
The Octagon Suite E2
2nd Floor Middleborough
Colchester
Essex
CO1 1TG
BLUEBELL AESTHETICS CLINIC LTD
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 7
BLUEBELL AESTHETICS CLINIC LTD
STATEMENT OF FINANCIAL POSITION
AS AT
31 MARCH 2026
31 March 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
4
159,394
156,763
Current assets
Stocks
21,117
22,676
Debtors
5
3,089
18,541
Cash at bank and in hand
892
707
25,098
41,924
Creditors: amounts falling due within one year
6
(361,042)
(275,977)
Net current liabilities
(335,944)
(234,053)
Total assets less current liabilities
(176,550)
(77,290)
Creditors: amounts falling due after more than one year
7
(2,325)
(37,336)
Provisions for liabilities
(28,001)
(27,000)
Net liabilities
(206,876)
(141,626)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
(206,976)
(141,726)
Total equity
(206,876)
(141,626)
BLUEBELL AESTHETICS CLINIC LTD
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 MARCH 2026
31 March 2026
- 2 -

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 1 July 2026 and are signed on its behalf by:
Mr V Shakthi
Director
Company registration number 11881781 (England and Wales)
BLUEBELL AESTHETICS CLINIC LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
1
Accounting policies
Company information

Bluebell Aesthetics Clinic Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 140 Tomswood Hill, Ilford, Essex, IG6 2QP.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The directors have assessed the going concern status of the company. That assessment includes the review of monthly management information, future cash flow and forecasted turnover for the next 12 months from the date of approval of these financial statements. Their assessment considers the impact of changes in interest rates and cost of living increases, as well as considering both the national and economic climate.

At 31 March 2026 the company has net liabilities of £206,876, of which £318,509 is amounts owed to connected companies. The directors consider that the company has continued shareholder support, sufficient liquid resources and access to future resources to enable to company to cover its costs and pay its liabilities for the next 12 months from the date of approval of these financial statements.

Consequently the directors have concluded that there are no material uncertainties that may cause significant doubt on the company’s ability to continue as a going concern for the 12 months from the date of approval of these financial statements. Accordingly, the going concern basis has been adopted in preparing the financial statements.

1.3
Revenue

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

BLUEBELL AESTHETICS CLINIC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
10% Straight line
Fixtures and fittings
20% Straight line
Computers
33.3% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

BLUEBELL AESTHETICS CLINIC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 5 -
1.10
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11
Leases
As lessee

Leases are classified as hire purchases whenever the terms of the hire purchase transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under hire purchase are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

BLUEBELL AESTHETICS CLINIC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 6 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
2
2
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2025
233,722
Additions
33,804
At 31 March 2026
267,526
Depreciation and impairment
At 1 April 2025
76,959
Depreciation charged in the year
31,173
At 31 March 2026
108,132
Carrying amount
At 31 March 2026
159,394
At 31 March 2025
156,763
5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Other debtors
3,089
18,541
6
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
6,461
2,438
Other creditors
354,581
273,539
361,042
275,977
BLUEBELL AESTHETICS CLINIC LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 7 -
7
Creditors: amounts falling due after more than one year
2026
2025
£
£
Other creditors
2,325
37,336
8
Operating lease commitments
As lessee

At the reporting end date the company had no further outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2026
2025
£
£
Total commitments
-
0
1,238
9
Directors' transactions

There have been no guarantees with the directors in the year.

2026-03-31 2025-04-01 false false false 01 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Dr S Shakthi Mr V Shakthi 11881781 2025-04-01 2026-03-31 11881781 2026-03-31 11881781 2025-03-31 11881781 core:OtherPropertyPlantEquipment 2026-03-31 11881781 core:OtherPropertyPlantEquipment 2025-03-31 11881781 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 11881781 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11881781 core:Non-currentFinancialInstruments core:AfterOneYear 2026-03-31 11881781 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 11881781 core:CurrentFinancialInstruments 2026-03-31 11881781 core:CurrentFinancialInstruments 2025-03-31 11881781 core:ShareCapital 2026-03-31 11881781 core:ShareCapital 2025-03-31 11881781 core:RetainedEarningsAccumulatedLosses 2026-03-31 11881781 core:RetainedEarningsAccumulatedLosses 2025-03-31 11881781 bus:Director2 2025-04-01 2026-03-31 11881781 core:PlantMachinery 2025-04-01 2026-03-31 11881781 core:FurnitureFittings 2025-04-01 2026-03-31 11881781 core:ComputerEquipment 2025-04-01 2026-03-31 11881781 2024-04-01 2025-03-31 11881781 core:OtherPropertyPlantEquipment 2025-03-31 11881781 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 11881781 core:Non-currentFinancialInstruments 2026-03-31 11881781 core:Non-currentFinancialInstruments 2025-03-31 11881781 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 11881781 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 11881781 bus:FRS102 2025-04-01 2026-03-31 11881781 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 11881781 bus:Director1 2025-04-01 2026-03-31 11881781 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP